Tags

Type your tag names separated by a space and hit enter

[Value of malarone in therapy of malaria tropica].
Med Klin (Munich). 2002 Aug 15; 97(8):455-8.MK

Abstract

BACKGROUND

A widespread resistance of falciparum malaria to common antimalaria drugs is observed during the last years. Long-distance travel to high-risk destinations of falciparum malaria will contribute to increased exposition of travelers to highly resistant parasites.

PHARMACOLOGY

Malarone (GlaxoSmithKline) is a fixed combination of atovaquone and proguanil licensed for prophylaxis and treatment of falciparum malaria. Both atovaquone and proguanil demonstrate synergistic activity against liver and blood schizonts. Malarone is well tolerated with a low rate of side effects. Malarone has an excellent efficacy profile in nonimmune subjects.

CONCLUSIONS

Malarone appears to be a valuable alternative malaria prophylaxis in case of intolerance of other antimalaria drugs. Atovaquone/proguanil is effective in treating acute uncomplicated malaria caused by multiresistant strains of Plasmodium falciparum.

Authors+Show Affiliations

Sophien und Hufeland Klinikum Weimar gGmbH. t.ziegler@klinikum_weimar.deNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

12229244

Citation

Ziegler, Tom, et al. "[Value of Malarone in Therapy of Malaria Tropica]." Medizinische Klinik (Munich, Germany : 1983), vol. 97, no. 8, 2002, pp. 455-8.
Ziegler T, Schau A, Winkler C. [Value of malarone in therapy of malaria tropica]. Med Klin (Munich). 2002;97(8):455-8.
Ziegler, T., Schau, A., & Winkler, C. (2002). [Value of malarone in therapy of malaria tropica]. Medizinische Klinik (Munich, Germany : 1983), 97(8), 455-8.
Ziegler T, Schau A, Winkler C. [Value of Malarone in Therapy of Malaria Tropica]. Med Klin (Munich). 2002 Aug 15;97(8):455-8. PubMed PMID: 12229244.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Value of malarone in therapy of malaria tropica]. AU - Ziegler,Tom, AU - Schau,Anja, AU - Winkler,Christina, PY - 2002/9/17/pubmed PY - 2002/12/20/medline PY - 2002/9/17/entrez SP - 455 EP - 8 JF - Medizinische Klinik (Munich, Germany : 1983) JO - Med Klin (Munich) VL - 97 IS - 8 N2 - BACKGROUND: A widespread resistance of falciparum malaria to common antimalaria drugs is observed during the last years. Long-distance travel to high-risk destinations of falciparum malaria will contribute to increased exposition of travelers to highly resistant parasites. PHARMACOLOGY: Malarone (GlaxoSmithKline) is a fixed combination of atovaquone and proguanil licensed for prophylaxis and treatment of falciparum malaria. Both atovaquone and proguanil demonstrate synergistic activity against liver and blood schizonts. Malarone is well tolerated with a low rate of side effects. Malarone has an excellent efficacy profile in nonimmune subjects. CONCLUSIONS: Malarone appears to be a valuable alternative malaria prophylaxis in case of intolerance of other antimalaria drugs. Atovaquone/proguanil is effective in treating acute uncomplicated malaria caused by multiresistant strains of Plasmodium falciparum. SN - 0723-5003 UR - https://www.unboundmedicine.com/medline/citation/12229244/[Value_of_malarone_in_therapy_of_malaria_tropica]_ L2 - https://dx.doi.org/10.1007/s00063-002-1179-z DB - PRIME DP - Unbound Medicine ER -